Leading Chinese humanoid robotics company that pivoted from rehabilitation robots to general-purpose humanoid robots. Founded in 2015 by Gu Jie (顾捷), a Shanghai Jiaotong University graduate with experience at FANUC and GM. Fourier's GR-1 (launched July 2023) was one of the first Chinese humanoid robots to achieve mass production delivery — 165cm tall, 55kg, 40 DOF. The GR-2 (September 2024) upgraded to 175cm, 63kg, 53 DOF with 12-DOF dexterous hands, single-arm 3kg payload, and 2-hour battery life. GR-2 introduced pure vision perception (BEV+Transformer+OCC with 6 RGB cameras). Also develops self-designed FSA (Force-controlled Series Actuator) joints. Rehabilitation robot business continues alongside humanoid development, with CE MDR Class II certified products deployed globally. In 2025, released open-source robot N1. Valued at ¥8 billion (~$1.1B) after E-round in January 2025, making it an official unicorn.
Shanghai, Shanghai · Founded 2015 · Company website
Humanoid and rehabilitation robotics pure-play.
One of China's leading humanoid robot companies, differentiated by rehabilitation robotics heritage giving real-world medical deployment experience. GR-1 was among the first Chinese humanoids to ship. 2025 target: thousands of units total, including 300 bipedal humanoids. Valued at ¥8B (~$1.1B) — officially a unicorn. Dual business line (rehab + humanoid) provides revenue stability that pure humanoid startups lack. Founder's background at FANUC provides deep robotics industry knowledge.
Fourier Intelligence launched its first wheeled dual-arm robot GRW, capable of lifting 16kg and swapping three end-effectors.
IT Zhijia (IT之家)This profile is part of the China Physical AI Index — a public information product published by Tech Buzz China for informational and educational purposes only. It is not investment advice and is not a recommendation regarding Fourier Intelligence or any other security. Company data is based on public filings and TBC research; revenue-exposure estimates are point-in-time and subject to update. See the full methodology §11 and disclaimer page.